PP2C family serine/threonine phosphatase WIP1 acts as a negative regulator of the tumor suppressor p53 and is implicated in silencing of cellular responses to genotoxic stress. Chromosomal locus 17q23 carrying the PPM1D (coding for WIP1) is commonly amplified in breast carcinomas and WIP1 was proposed as potential pharmacological target. Here we employed a cellular model with knocked out PPM1D to validate the specificity and efficiency of GSK2830371, novel small molecule inhibitor of WIP1. We have found that GSK2830371 increased activation of the DNA damage response pathway to a comparable level as the loss of PPM1D. In addition, GSK2830371 did not affect proliferation of cells lacking PPM1D but significantly supressed proliferation of breast cancer cells with amplified PPM1D. Over time cells treated with GSK2830371 accumulated in G1 and G2 phases of the cell cycle in a p21-dependent manner and were prone to induction of senescence by a low dose of MDM2 antagonist nutlin-3. In addition, combined treatment with GSK2830371 and doxorubicin or nutlin-3 potentiated cell death through a strong induction of p53 pathway and activation of caspase 9. We conclude that efficient inhibition of WIP1 by GSK2830371 sensitizes breast cancer cells with amplified PPM1D and wild type p53 to chemotherapy.

Department of Cancer Cell Biology Institute of Molecular Genetics of the ASCR CZ 14220 Prague Czech Republic

Institute of Biochemistry and Experimental Oncology Charles University Prague CZ 12853 Prague Czech Republic

Zobrazit více v PubMed

Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–1078. PubMed PMC

Halazonetis TD, Gorgoulis VG, Bartek J. An Oncogene-Induced DNA Damage Model for Cancer Development. Science. 2008;319:1352–1355. PubMed

Leontieva O, Gudkov A, Blagosklonny M. Weak p53 permits senescence during cell cycle arrest. Cell Cycle. 2010;9:4323–7. PubMed

Kracikova M, Akiri G, George A, Sachidanandam R, Aaronson SA. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death and Differentiation. 2013;20:576–588. PubMed PMC

Zhang X-P, Liu F, Cheng Z, Wang W. Cell fate decision mediated by p53 pulses. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:12245–12250. PubMed PMC

Pei D, Zhang Y, Zheng J. Regulation of p53: a collaboration between Mdm2 and MdmX. Oncotarget. 2012;3:228–235. doi: 10.18632/oncotarget.443. PubMed DOI PMC

Popowicz G, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, Weber L, Holak T. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle. 2007;6:2386–92. PubMed

Meulmeester E, Pereg Y, Shiloh Y, Jochemsen A. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle. 2005;4:1166–70. PubMed

Shieh SY, Ikeda M, Taya Y, Prives C. DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2. Cell. 1997;91:325–334. PubMed

Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh S-Y, Taya Y, Prives C, Abraham RT. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes & Development. 1999;13:152–157. PubMed PMC

Jenkins LMM, Durell SR, Mazur SJ, Appella E. p53 N-terminal phosphorylation: a defining layer of complex regulation. Carcinogenesis. 2012;33:1441–1449. PubMed PMC

Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Vande Woude GF, O Connor PM, Appella E. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA. 1997;94:6048–6053. PubMed PMC

Lu X, Nannenga B, Donehower L. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes & Development. 2005;19:1162–74. PubMed PMC

Lu X, Ma O, Nguyen T-A, Jones SN, Oren M, Donehower LA. The Wip1 Phosphatase Acts as a Gatekeeper in the p53-Mdm2 Autoregulatory Loop. Cancer Cell. 2007;12:342–354. PubMed

Lu X, Nguyen T, Zhang X, Donehower L. The Wip1 phosphatase and Mdm2: cracking the “Wip” on p53 stability. Cell Cycle. 2008;7:164–168. PubMed

Zhang X, Lin L, Guo H, Yang J, Jones SN, Jochemsen A, Lu X. Phosphorylation and Degradation of MdmX Is Inhibited by Wip1 Phosphatase in the DNA Damage Response. Cancer Research. 2009;69:7960–7968. PubMed PMC

Lindqvist A, de Bruijn M, Macurek L, Bras A, Mensinga A, Bruinsma W. Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional repression. EMBO J. 2009;28:3196–3206. PubMed PMC

Shaltiel IA, Aprelia M, Saurin AT, Chowdhury D, Kops GJPL, Voest EE, Medema RH. Distinct phosphatases antagonize the p53 response in different phases of the cell cycle. PNAS. 2014;111:7313–7318. PubMed PMC

Shreeram S, Demidov ON, Hee WK, Yamaguchi H, Onishi N, Kek C, Timofeev ON, Dudgeon C, Fornace AJ, Anderson CW, Minami Y, Appella E, Bulavin DV. Wip1 Phosphatase Modulates ATM-Dependent Signaling Pathways. Mol. Cell. 2006;23:757–764. PubMed

Macurek L, Lindqvist A, Voets O, Kool J, Vos H, Medema R. Wip1 phosphatase is associated with chromatin and dephosphorylates gammaH2AX to promote checkpoint inhibition. Oncogene. 2010;15(29):2281–91. PubMed

Le Guezennec X, Bulavin DV. WIP1 phosphatase at the crossroads of cancer and aging. Trends in Biochemical Sciences. 2010;35:109–114. PubMed

Moon S, Lin L, Zhang X, Nguyen T, Darlington Y, Waldman A, Lu X, LA D. Wildtype p53-induced phosphatase 1 dephosphorylates histone variant gamma-H2AX and suppresses DNA double strand break repair. J Biol Chem. 2010;23(285):12935–47. PubMed PMC

Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H, Taya Y, Imai K. p53-inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J. 2000;19:6517–6526. PubMed PMC

Fujimoto H, Onishi N, Kato N, Takekawa M, Xu X, Kosugi A. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ. 2006;13:1170–1180. PubMed

Lee JS, Lee MO, Moon BH, Shim SH, Fornace AJ, Cha H-J. Senescent Growth Arrest in Mesenchymal Stem Cells Is Bypassed by Wip1-Mediated Downregulation of Intrinsic Stress Signaling Pathways. STEM CELLS. 2009;27:1963–1975. PubMed

Sakai H, Fujigaki H, Mazur SJ, Appella E. Wild-type p53-induced phosphatase 1 (Wip1) forestalls cellular premature senescence at physiological oxygen levels by regulating DNA damage response signaling during DNA replication. Cell Cycle. 2014;13:1015–1029. PubMed PMC

Satoh N, Maniwa Y, Bermudez VP, Nishimura K, Nishio W, Yoshimura M, Okita Y, Ohbayashi C, Hurwitz J, Hayashi Y. Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival. Cancer Science. 2011;102:1101–6. PubMed PMC

Castellino R, De Bortoli M, Lu X, Moon S-H, Nguyen T-A, Shepard M, Rao P, Donehower L, Kim J. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J. Neurooncol. 2008;86:245–256. PubMed PMC

Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KCQ, Gabriele T, McCurrach ME, Marks JR, Hoey T, Lowe SW, Powers S. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet. 2002;31:133–134. PubMed

Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, Inazawa J. PPM1D Is a Potential Target for 17q Gain in Neuroblastoma. Cancer Res. 2003;63:1876–1883. PubMed

Bulavin DV, Demidov ON, Saito Si, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ, Appella E. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet. 2002;31:210–215. PubMed

Tan DSP, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar J, Thomas K, Natrajan R, Savage K, et al. Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas. Clinical Cancer Research. 2011;17:1521–1534. PubMed

Liang C, Guo E, Lu S, Wang S, Kang C, Chang L, Liu L, Zhang G, Wu Z, Zhao Z, Ma S, Wang L, Jiao B-h. Over-expression of Wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas. Brain Research. 2012;1444:65–75. PubMed

Rauta J, Alarmo E-L, Kauraniemi P, Karhu R, Kuukasjärvi T, Kallioniemi A. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Research and Treatment. 2006;95:257–263. PubMed

The Cancer Genome Atlas N Comprehensive molecular portraits of human breast tumors. Nature. 2012;490:61–70. PubMed PMC

Emelyanov A, Bulavin DV. Wip1 phosphatase in breast cancer. Oncogene. 2015;34:4429–4438. PubMed

Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E, Bulavin DV. The role of the MKK6//p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene. 2006;26:2502–2506. PubMed

Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, Rodrigues DN, Renwick A, Seal S, Ramsay E, Duarte SDV, Rivas MA, Warren-Perry M, et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013;493:406–410. PubMed PMC

Kleiblova P, Shaltiel IA, Benada J, Sevčík J, Pecháčková S, Pohlreich P, Voest EE, Dundr P, Bartek J, Kleibl Z, Medema RH, Macurek L. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. The Journal of Cell Biology. 2013;201:511–521. PubMed PMC

Dudgeon C, Shreeram S, Tanoue K, Mazur SJ, Sayadi A, Robinson RC, Appella E, Bulavin DV. Genetic variants and mutations of PPM1D control the response to DNA damage. Cell Cycle. 2013;12:2656–2664. PubMed PMC

Hoe KK, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014;13:217–236. PubMed

Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9:862–873. PubMed

Dong P, Ihira K, Hamada J, Watari H, Yamada T, Hosaka M, Hanley SJB, Kudo M, Sakuragi N. Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors. Oncotarget. 2015;6:19968–75. doi: 10.18632/oncotarget.4847. PubMed DOI PMC

Qin J-J, Wang W, Voruganti S, Wang H, Zhang W-D, Zhang R. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. Oncotarget. 2015;6:2623–40. doi: 10.18632/oncotarget.3098. PubMed DOI PMC

Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, et al. Identification and Characterization of the First Small Molecule Inhibitor of MDMX. Journal of Biological Chemistry. 2010;285:10786–10796. PubMed PMC

Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. Science. 2004;303:844–848. PubMed

Ding Q, Zhang Z, Liu J-J, Jiang N, Zhang J, Ross TM, Chu X-J, Bartkovitz D, Podlaski F, Janson C, Tovar C, Filipovic ZM, Higgins B, et al. Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development. Journal of Medicinal Chemistry. 2013;56:5979–5983. PubMed

Harrison M, Li J, Degenhardt Y, Hoey T, Powers S. Wip1-deficient mice are resistant to common cancer genes. Trends Mol Med. 2004;10:359–361. PubMed

Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E, Fornace AJ. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16Ink4a-p19Arf pathway. Nat Genet. 2004;36:343–350. PubMed

Shreeram S, Hee WK, Demidov ON, Kek C, Yamaguchi H, Fornace AJ, Jr, Anderson CW, Appella E, Bulavin DV. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J. Exp. Med. 2006;203:2793–2799. PubMed PMC

Demidov ON, Timofeev O, Lwin HNY, Kek C, Appella E, Bulavin DV. Wip1 Phosphatase Regulates p53-Dependent Apoptosis of Stem Cells and Tumorigenesis in the Mouse Intestine. Cell Stem Cell. 2007;1:180–190. PubMed

Demidov ON, Zhu Y, Kek C, Goloudina AR, Motoyama N, Bulavin DV. Role of Gadd45a in Wip1-dependent regulation of intestinal tumorigenesis. Cell Death and Differentiation. 2012;19:1761–1768. PubMed PMC

Pärssinen J, Alarmo E-L, Karhu R, Kallioniemi A. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53. Cancer Genetics and Cytogenetics. 2008;182:33–39. PubMed

Tan DSP, Lambros MBK, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, et al. PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas. Clinical Cancer Research. 2009;15:2269–2280. PubMed

Wang P, Rao J, Yang H, Zhao H, Yang L. PPM1D silencing by lentiviral-mediated RNA interference inhibits proliferation and invasion of human glioma cells. Journal of Huazhong University of Science and Technology. 2011;31:94–99. PubMed

Yamaguchi H, Durell SR, Feng H, Bai Y, Anderson CW, Appella E. Development of a Substrate-Based Cyclic Phosphopeptide Inhibitor of Protein Phosphatase 2Cδ, Wip1†. Biochemistry. 2006;45:13193–13202. PubMed

Hayashi R, Tanoue K, Durell SR, Chatterjee DK, Miller Jenkins LM, Appella DH, Appella E. Optimization of a Cyclic Peptide Inhibitor of Ser/Thr Phosphatase PPM1D (Wip1) Biochemistry. 2011;50:4537–4549. PubMed PMC

Rayter S, Elliott R, Travers J, Rowlands MG, Richardson TB, Boxall K, Jones K, Linardopoulos S, Workman P, Aherne W, Lord CJ, Ashworth A. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene. 2007;27:1036–1044. PubMed

Lee JS, Park JR, Kwon OS, Kim H, Fornace AJ, Cha HJ. Off-target response of a Wip1 chemical inhibitor in skin keratinocytes. Journal of Dermatological Science. 2014;73:125–134. PubMed

Yagi H, Chuman Y, Kozakai Y, Imagawa T, Tkahashi Y, Yoshimura F, Tanino K, Sakaguchi K. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D. Bioorg Med Chem Lett. 2012;22:729–32. PubMed

Kozakai Y, Kamada R, Kiyota Y, Yoshimura F, Tanino K, Sakaguchi K. Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line. Bioorganic & Med. Chem. Lett. 2014;24:5593–5596. PubMed

Ogasawara S, Kiyota Y, Chuman Y, Kowata A, Yoshimura F, Tanino K, Kamada R, Sakaguchi K. Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation. Bioorganic & Medicinal Chemistry. 2015;23:6246–6249. PubMed

Gilmartin AG, Faitg TH, Richter M, Groy A, Seefeld MA, Darcy MG, Peng X, Federowicz K, Yang J, Zhang S-Y, Minthorn E, Jaworski J-P, Schaber M, et al. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. Nat Chem Biol. 2014;10:181–187. PubMed

Richter M, Dayaram T, Gilmartin AG, Ganji G, Pemmasani SK, Van Der Key H, Shohet JM, Donehower LA, Kumar R. WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma. PLoS ONE. 2015;10:e0115635. PubMed PMC

Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Research. 2015;43:D805–D811. PubMed PMC

Macurek L, Benada J, Müllers E, Halim VA, Krejčíková K, Burdová K, Pecháčková S, Hodný Z, Lindqvist A, Medema RH, Bartek J. Downregulation of Wip1 phosphatase modulates the cellular threshold of DNA damage signaling in mitosis. Cell Cycle. 2013;12:251–262. PubMed PMC

Hock AK, Vousden KH. The role of ubiquitin modification in the regulation of p53. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2014;1843:137–149. PubMed

Kruse J-P, Gu W. Modes of p53 Regulation. Cell. 2009;137:609–622. PubMed PMC

Mirza A, McGuirk M, Hockenberry T, Wu Q, Ashar H, Black S, Wen S, Wang L, Kirschmeier P, Bishop W, Nielsen L, Pickett C, Liu S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21:2613–2622. PubMed

Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53. Journal of Biological Chemistry. 2002;277:3247–3257. PubMed

Lam S, Lodder K, Teunisse AFAS, Rabelink MJWE, Schutte M, Jochemsen AG. Role of Mdm4 in drug sensitivity of breast cancer cells. Oncogene. 2010;29:2415–2426. PubMed

Johnson C, Jarvis W. Caspase-9 regulation: an update. Apoptosis. 2004;9:423–7. PubMed

Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat. Protocols. 2009;4:1798–1806. PubMed

Choi J, Nannenga B, Demidov O, Bulavin D, Cooney A, Brayton C. Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol. 2002;22:1094–1105. PubMed PMC

Spencer Sabrina L, Cappell Steven D, Tsai F-C, Overton KW, Wang Clifford L, Meyer T. The Proliferation-Quiescence Decision Is Controlled by a Bifurcation in CDK2 Activity at Mitotic Exit. Cell. 2013;155:369–383. PubMed PMC

Overton KW, Spencer SL, Noderer WL, Meyer T, Wang CL. Basal p21 controls population heterogeneity in cycling and quiescent cell cycle states. Proceedings of the National Academy of Sciences. 2014;111:E4386–E4393. PubMed PMC

Krenning L, Feringa Femke M, Shaltiel Indra A, van den Berg J, Medema René H. Transient Activation of p53 in G2 Phase Is Sufficient to Induce Senescence. Molecular Cell. 2014;55:59–72. PubMed

Müllers E, Cascales HS, Jaiswal H, Saurin AT, Lindqvist A. Nuclear translocation of Cyclin B1 marks the restriction point for terminal cell cycle exit in G2 phase. Cell Cycle. 2014;13:2733–2743. PubMed PMC

Kong W, Jiang X, Mercer W. Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax. Cancer Biol Ther. 2009;8:555–63. PubMed

Coll-Mulet L, Iglesias-Serret D, Santidrián AF, Cosialls AM, de Frias M, Castaño E, Campàs C, Barragán M, de Sevilla AF, Domingo A, Vassilev LT, Pons G, Gil J. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 2006;107:4109–4114. PubMed

Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa L-F, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, et al. p53 in breast cancer subtypes and new insights into response to chemotherapy. The Breast. 2013;22(Supplement 2):S27–S29. PubMed

Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK, Lozano G. p53 mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell. 2012;21:793–806. PubMed PMC

Rochette L, Guenancia C, Gudjoncik A, Hachet O, Zeller M, Cottin Y, Vergely C. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends in Pharmacological Sciences. 2015;36:326–348. PubMed

Song JY, Ryu SH, Cho YM, Kim YS, Lee BM, Lee SW, Choi J. Wip1 suppresses apoptotic cell death through direct dephosphorylation of BAX in response to γ-radiation. Cell Death & Disease. 2013;4:e744. PubMed PMC

Goloudina AR, Tanoue K, Hammann A, Fourmaux E, Le Guezennec X, Bulavin DV, Mazur SJ, Appella E, Garrido C, Demidov ON. Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proceedings of the National Academy of Sciences. 2012;109:E68–E75. PubMed PMC

Goloudina AR, Mazur SJ, Appella E, Garrido C, Demidov ON. Wip1 sensitizes p53-negative tumors to apoptosis by regulating the Bax/Bcl-xL ratio. Cell Cycle. 2012;11:1883–1887. PubMed PMC

Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin. J Biol Chem. 2006;281:33030–33035. PubMed

Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle. 2008;7:1604–1612. PubMed

Quah BJC, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat. Protocols. 2007;2:2049–2056. PubMed

Gary RK, Kindell SM. Quantitative assay of senescence-associated β-galactosidase activity in mammalian cell extracts. Analytical Biochemistry. 2005;343:329–334. PubMed

Harnessing p53 for targeted cancer therapy: new advances and future directions

PPM1D activity promotes cellular transformation by preventing senescence and cell death

PPM1D activity promotes the replication stress caused by cyclin E1 overexpression

Phosphorylation of TRF2 promotes its interaction with TIN2 and regulates DNA damage response at telomeres

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

Design, synthesis, and in vitro evaluation of BP-1-102 analogs with modified hydrophobic fragments for STAT3 inhibition

Cyclin A2 localises in the cytoplasm at the S/G2 transition to activate PLK1

Truncated PPM1D Prevents Apoptosis in the Murine Thymus and Promotes Ionizing Radiation-Induced Lymphoma

A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants

Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors

WIP1 phosphatase as pharmacological target in cancer therapy